GILD
Gilead Sciences, Inc.
- EBITDA, 2025
- $12.8B
- YoY, 2025
- +188.6%
- 5-year CAGR
- +18.2%
- 10-year CAGR
- −5.8%
EBITDA
EBITDA by fiscal year
| Period | EBITDA | YoY |
|---|---|---|
| 2025 | $12.8B | +188.6% |
| 2024 | $4.4B | −57.0% |
| 2023 | $10.3B | +9.2% |
| 2022 | $9.4B | −21.2% |
| 2021 | $12.0B | +115.6% |
| 2020 | $5.6B | −2.5% |
| 2019 | $5.7B | −40.9% |
| 2018 | $9.6B | −37.5% |
| 2017 | $15.4B | −18.0% |
| 2016 | $18.8B | −19.3% |
| 2015 | $23.3B | +42.8% |
| 2014 | $16.3B | +235.1% |
| 2013 | $4.9B | +13.5% |
| 2012 | $4.3B | +4.8% |
| 2011 | $4.1B | −3.2% |
| 2010 | $4.2B | +13.0% |
| 2009 | $3.7B | +32.0% |
| 2008 | $2.8B | +25.1% |
| 2007 | $2.3B | — |